Cardiol Therapeutics Stock (NASDAQ:CRDL)

Forecast Ownership Financials Chart

Previous Close

$1.31

52W Range

$0.79 - $3.12

50D Avg

$1.71

200D Avg

$1.95

Market Cap

$104.45M

Avg Vol (3M)

$483.35K

Beta

0.70

Div Yield

CRDL Company Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jan 15, 2019

Website

CRDL Performance

CRDL Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	-	$78.76K
Operating Income	$-29.79M	$-50.34M	$-45.47M
Net Income	$-28.13M	$-30.93M	$-31.64M
EBITDA	$-29.54M	$-50.12M	$-45.25M
Basic EPS	$-0.44	$-0.49	$-0.73
Diluted EPS	$-0.44	$-0.49	$-0.73

Fiscal year ends in Dec 23 | Currency in CAD

Peer Comparison

Ticker	Company
ABVC	ABVC BioPharma, Inc.
PRFX	PainReform Ltd.
FLGC	Flora Growth Corp.
HCWB	HCW Biologics Inc.
INDP	Indaptus Therapeutics, Inc.